



The authors reply: Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions

Ethan L Matz, Amy M Pearlman, Ryan P Terlecki

Department of Urology, Wake Forest Baptist Medical Center, Winston Salem, NC, USA

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

To the editor:

Thank you for addressing a very interesting and important question. As you mention, our study reports on the safety and feasibility of platelet rich plasma (PRP) in the treatment of common urologic conditions, including erectile dysfunction, Peyronie's disease, and stress urinary incontinence. None of our patients, however, had a history of cancer, so we cannot say whether this therapy is safe in those types of patients as it concerns tumorigenicity and recurrence. We are currently working with Dr. John Jackson's Lab at the Wake Forest Institute for Regenerative Medicine to study stem cell therapy in the cavernous nerve

crush model as well as PRP and its associated growth factors that may play a role in tissue regeneration. We do not, however, have any data on the implication of these therapies in animals or humans with a history of cancer. We certainly agree that the role of PRP in nerve regeneration after tumor excision deserves further experimental investigation and we thank you for discussing this very salient point.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

Received: 28 May, 2018 • **Accepted:** 31 May, 2018

Corresponding Author: Ryan P Terlecki

Department of Urology, Wake Forest Baptist Medical Center, Medical Center Blvd Winston Salem, NC 27157, USA

TEL: +1-336-716-5690, FAX: +1-336-716-5711, E-mail: rterlecki@wakehealth.edu

ORCID: <http://orcid.org/0000-0002-7003-0497>